CME / ABIM MOC / CE

EGFR Exon 20 Insertion Mutations in NSCLC: Underscoring the Value of Detection and Subsequent Care

Authors: Keith M. Kerr, MB ChB, FRCPath; Joshua Sabari, MD; Victoria E. Sherry, DNP, CRNP, AOCNP; Gerard A. Silvestri, MD, MS
CME / ABIM MOC / CE Released: 7/31/2023
Valid for credit through: 7/31/2024, 11:59 PM EST

Credits Available

Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 0.50 ABIM MOC points

Nurses - 0.50 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

IPCE - 0.50 Interprofessional Continuing Education (IPCE) credit

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for pathologists, oncologists, pulmonologists, midlevel providers, pharmacists, nurses, and other members of the care team.

The goal of this activity is for learners to be better able to recognize and implement appropriate testing and detection methods for the comprehensive care of EGFR exon 20 insertion-positive NSCLC.

Upon completion of this activity, participants will:

Have greater competence related to
- Detecting EGFR exon 20 insertions in patients with NSCLC
- Interpreting next-generation sequencing (NGS) test results
- Creating customized care plans for patients with NSCLC and EGFR exon 20 insertions
Demonstrate greater confidence in their ability to
- Collaborate with the interprofessional team to optimize care for patients with NSCLC and EGFR exon 20 insertions

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Keith M. Kerr, MB ChB, FRCPath

Professor of Pathology
Aberdeen University School of Medicine
Consultant Pathologist
Aberdeen Royal Infirmary
Aberdeen, Scotland, United Kingdom

Disclosures

Keith M. Kerr, MB ChB, FRCPath, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; Amgen Inc.; AstraZeneca; Diaceutics; Janssen Pharmaceuticals; Merck Serono; Merck Sharp & Dohme; Novartis Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Roche; Takeda; Ventana
Speaker or member of speakers bureau for: Amgen Inc.; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Janssen Pharmaceuticals; Merck Serono; Merck Sharp & Dohme; Novartis Pharmaceuticals; Pfizer, Inc.; Roche; Ventana

Joshua Sabari, MD

Assistant Professor of Medicine
NYU Langone Health
Perlmutter Cancer Center
New York, New York, United States

Disclosures

Joshua Sabari, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; AstraZeneca; Genentech, Inc.; Janssen Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Mirati; Navire; Novocure; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme Corporation; Takeda
Research funding from: AstraZeneca; Janssen Pharmaceuticals; Mirati; Regeneron Pharmaceuticals, Inc.

Victoria E. Sherry, DNP, CRNP, AOCNP

Oncology Nurse Practitioner for Thoracic Malignancies
Abramson Cancer Center
Penn Medicine
Faculty
University of Pennsylvania School of Nursing
Philadelphia, Pennsylvania, United States

Disclosures

Victoria E. Sherry, DNP, CRNP, AOCNP, has no relevant financial relationships.

Gerard A. Silvestri, MD, MS

Endowed Chair, George C. And Margaret M. Hillenbrand
Professor of Medicine
Medical University of South Carolina
Charleston, South Carolina, United States

Disclosures

Gerard A. Silvestri, MD, MS, has the following relevant financial relationships:
Consultant or advisor for: Biodesix; Freenome; Johnson and Johnson; Olympus America; PrognomIQ
Speaker or member of speakers bureau for: Amgen Inc.; AstraZeneca
Research funding from: Amgen Inc.; Auris; Biodesix; Delfi; Freenome; Nucleix; Olympus America; PrognomIQ; QureAI

Editors

Amy Furedy, RN, OCN

Medical Education Director, Medscape, LLC

Disclosures

Amy Furedy, RN, OCN, has no relevant financial relationships.

John Churchwell, MS, PhD

Medical Education Director, Medscape, LLC

Disclosures

John Churchwell, MS, PhD, has the following relevant financial relationships:
Previously employed by Medtronic.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

Developed through a partnership between Medscape and Association for Molecular Pathology.

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

Contact This Provider

For Nurses

Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-23-309-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Pathology

CME / ABIM MOC / CE

EGFR Exon 20 Insertion Mutations in NSCLC: Underscoring the Value of Detection and Subsequent Care

Authors: Keith M. Kerr, MB ChB, FRCPath; Joshua Sabari, MD; Victoria E. Sherry, DNP, CRNP, AOCNP; Gerard A. Silvestri, MD, MSFaculty and Disclosures

CME / ABIM MOC / CE Released: 7/31/2023

Valid for credit through: 7/31/2024, 11:59 PM EST

processing....

Contents of This CME Activity

To start this activity, please assess your clinical knowledge by completing the brief survey at the bottom. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Rationale for Identifying EGFR Exon 20 Insertions in NSCLC

Curious to find out what percentage of variants are EGFR exon 20 insertions?
Joshua Sabari, MD; Keith M. Kerr, MB ChB, FRCPath

Tissue Acquisition and Identifying Molecular Alterations (Including EGFR Exon 20 Insertion) in NSCLC: What Works Best?

How much tissue is enough and what's the best method for identifying molecular alterations?
Keith M. Kerr, MB ChB, FRCPath; Gerard A. Silvestri, MD, MS

NGS Reporting and Implications for Clinical Practice

Learn about the best testing modality for EGFR exon 20 insertions in this informative conversation.
Keith M. Kerr, MB ChB, FRCPath; Joshua Sabari, MD

Discussing the Therapeutic Options for the Patient With EGFR Exon 20 Insertion-Positive NSCLC

Do you know what therapies are available for treating EGFR exon 20 insertion-positive NSCLC?
Joshua Sabari, MD

Communicating With the Patient: The Role of the Interprofessional Team

Drs Sabari and Sherry discuss factors that influence treatment choice and the necessity of good patient communication.
Joshua Sabari, MD; Victoria E. Sherry, DNP, CRNP, AOCNP

Educational Impact Challenge

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

Page 1 of 8

CME / ABIM MOC / CE Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Keith M. Kerr, MB ChB, FRCPath

Joshua Sabari, MD

Victoria E. Sherry, DNP, CRNP, AOCNP

Gerard A. Silvestri, MD, MS

Editors

Amy Furedy, RN, OCN

John Churchwell, MS, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME / ABIM MOC / CE

EGFR Exon 20 Insertion Mutations in NSCLC: Underscoring the Value of Detection and Subsequent Care

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Keith M. Kerr, MB ChB, FRCPath

Joshua Sabari, MD

Victoria E. Sherry, DNP, CRNP, AOCNP

Gerard A. Silvestri, MD, MS

Editors

Amy Furedy, RN, OCN

John Churchwell, MS, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

EGFR Exon 20 Insertion Mutations in NSCLC: Underscoring the Value of Detection and Subsequent Care

Contents of This CME Activity

Rationale for Identifying EGFR Exon 20 Insertions in NSCLC

Tissue Acquisition and Identifying Molecular Alterations (Including EGFR Exon 20 Insertion) in NSCLC​: What Works Best?

NGS Reporting and Implications for Clinical Practice

Discussing the Therapeutic​ Options for the Patient With EGFR Exon 20 Insertion-Positive NSCLC​

Communicating With​ the Patient​: The Role of the Interprofessional Team

Educational Impact Challenge

Tissue Acquisition and Identifying Molecular Alterations (Including EGFR Exon 20 Insertion) in NSCLC: What Works Best?

Discussing the Therapeutic Options for the Patient With EGFR Exon 20 Insertion-Positive NSCLC

Communicating With the Patient: The Role of the Interprofessional Team